Holen Sie sich die Stockscreener-App
11.06
1.10%
0.12
Vorhandelsmarkt:
11.44
0.38
+3.44%
Schlusskurs vom Vortag:
$10.94
Offen:
$10.9
24-Stunden-Volumen:
1.80M
Relative Volume:
0.93
Marktkapitalisierung:
$750.14M
Einnahmen:
$65,400
Nettoeinkommen (Verlust:
$-46.34M
KGV:
-12.02
EPS:
-0.92
Netto-Cashflow:
$-38.74M
1W Leistung:
-2.73%
1M Leistung:
-18.74%
6M Leistung:
-10.08%
1J Leistung:
+133.33%
1-Tages-Spanne:
$10.70
$11.15
1-Wochen-Bereich:
$10.70
$11.59
52-Wochen-Spanne:
$3.61
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Firmenname
CorMedix Inc
Sektor
Branche
Telefon
908-517-9500
Adresse
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Vergleichen Sie CRMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
11.06 | 846.26M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-13 | Eingeleitet | D. Boral Capital | Buy |
| 2024-08-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-02-17 | Eingeleitet | Needham | Buy |
| 2020-09-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-09-21 | Eingeleitet | Truist | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2019-03-26 | Bestätigt | H.C. Wainwright | Buy |
| 2018-12-06 | Eingeleitet | ROTH Capital | Buy |
| 2017-09-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-08-10 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-05-05 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-11-11 | Bestätigt | FBR & Co. | Outperform |
| 2016-03-17 | Bestätigt | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | FBR Capital | Outperform |
| 2015-11-16 | Bestätigt | ROTH Capital | Neutral |
| 2015-10-29 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Bestätigt | ROTH Capital | Buy |
| 2011-10-03 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
What drives CorMedix Inc. stock priceStrong return on assets - Autocar Professional
What analysts say about CorMedix Inc. stockMassive portfolio appreciation - jammulinksnews.com
Is CorMedix Inc. a good long term investmentUnmatched market performance - Autocar Professional
CorMedix Inc. Stock Analysis and ForecastFree Stock Market Knowledge Sharing - jammulinksnews.com
CorMedix Inc. (CRMD) Plunges 1.90% to 2025 Low - AInvest
Why CorMedix Inc. stock attracts strong analyst attentionFree Access to Community - Newser
What makes CorMedix Inc. stock price move sharplyFree Consultation - Newser
How CorMedix Inc. stock performs during market volatilityHigh Potential Safe Trades - Newser
CorMedix soars on increased Q2 sales guidance - MSN
Can CorMedix (CRMD) Keep the Earnings Surprise Streak Alive? - Yahoo Finance
CorMedix’s DEFENCATH® Study: A Potential Game-Changer in Infection Prevention - MSN
CorMedix Inc. Advances Pediatric Dialysis Safety with New Clinical Study - TipRanks
(CRMD) Investment Analysis and Advice - news.stocktradersdaily.com
Important Notice to Long-Term Shareholders of CorMedix Inc. - GlobeNewswire
RBC Capital Maintains CorMedix(CRMD.US) With Buy Rating, Raises Target Price to $18 - 富途牛牛
Important Notice to Long-Term Shareholders of AdaptHealth Corp. (NASDAQ: AHCO); CorMedix Inc. (NASDAQ: CRMD); Napco Security Technologies, Inc. (NASDAQ: NSSC); and Virtu Financial Inc. (NYSE: VIRT): Grabar Law Office is Investigating Claims on - GlobeNewswire
Important Notice to Long-Term Shareholders of AdaptHealth Corp. (NASDAQ: AHCO); CorMedix Inc. ... - Bluefield Daily Telegraph
CorMedix Completes $82.2 Million Stock Offering - The Globe and Mail
CorMedix stock rating downgraded to Hold from Buy by D. Boral Capital - Investing.com
CorMedix stock rating reiterated as Buy by H.C. Wainwright - Investing.com India
CorMedix slides after pricing $85M stock offering - MSN
CorMedix prices $85 million public offering of common stock By Investing.com - Investing.com South Africa
CorMedix Stock Tumbles After $85M Stock Sale; But Retail Sees Bargain In DefenCath Bet - Asianet Newsable
CorMedix plans $85 million common stock offering - Investing.com India
CorMedix stock falls after $85 million share offering announcement - Investing.com
CorMedix stock falls after $85 million share offering announcement By Investing.com - Investing.com UK
CorMedix shareholders approve board nominees and key proposals at annual meeting - Investing.com
CorMedix stock rises as Truist reiterates buy on expanded DefenCath rollout - Investing.com Canada
CorMedix Lifts Q2 Outlook As Dialysis Partner Expands DefenCath Use; Needham Raises PT To $20 - Stocktwits
CorMedix inc. Announces Customer Implementation - The Manila Times
CorMedix Expands DefenCath Implementation with Major Client - TipRanks
Cormedix (CRMD) Receives a Rating Update from a Top Analyst - The Globe and Mail
CorMedix price target raised to $17 from $13 at RBC Capital - TipRanks
Learn to Evaluate (CRMD) using the Charts - news.stocktradersdaily.com
CorMedix stock price target raised to $17 from $13 at RBC Capital - Investing.com
CorMedix Inc.'s (NASDAQ:CRMD) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - Yahoo Finance
Despite shrinking by US$64m in the past week, CorMedix (NASDAQ:CRMD) shareholders are still up 366% over 3 years - simplywall.st
CorMedix stock rises after earnings, revenue beat - MSN
CorMedix stock soars to 52-week high, hits $15.33 By Investing.com - Investing.com South Africa
CorMedix stock soars to 52-week high, hits $15.33 - Investing.com Australia
Finanzdaten der CorMedix Inc-Aktie (CRMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):